A Population-based Study Comparing Outcomes for Patients With Metastatic Castrate Resistant Prostate Cancer Treated by Urologists or Medical Oncologists With First Line Abiraterone Acetate or Enzalutamide-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A Population-based Study Comparing Outcomes for Patients With Metastatic Castrate Resistant Prostate Cancer Treated by Urologists or Medical Oncologists With First Line Abiraterone Acetate or Enzalutamide

Published:2021-07 Issue: Volume:153 Page:147-155
ISSN:0090-4295
Container-title:Urology
language:en
Short-container-title:Urology

Author:

Woon Dixon T.S.,Finelli Antonio,Cheung Douglas C.,Martin Lisa J.,Alibhai Shabbir,Wallis Christopher J.D,Diong Christina,Saskin Refik,Kulkarni Girish,Fleshner Neil

Funder

Institute for Clinical Evaluative Sciences

Janssen Pharmaceuticals

Ontario Ministry of Health and Long-Term Care

Princess Margaret Cancer Foundation

Bayer

Merck

Astellas Pharma Canada

Publisher

Elsevier BV

Subject

Urology

Reference18 articles.

1. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer;Tannock;N Engl J Med,2004

2. Abiraterone and increased survival in metastatic prostate cancer;de Bono;N Engl J Med,2011

3. Increased survival with enzalutamide in prostate cancer after chemotherapy;Scher;N Engl J Med,2012

4. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study;Ryan;Lancet Oncol,2015

5. Enzalutamide in men with chemotherapy-naïve metastatic castration-resistant prostate cancer: extended analysis of the Phase 3 PREVAIL study;Beer;Eur Urol,2017

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world outcomes for first line next-generation hormonal agents in metastatic prostate cancer: a systematic review;Future Oncology;2023-11

2. Outcomes Following Abiraterone versus Enzalutamide for Prostate Cancer: A Scoping Review;Cancers;2022-08-03

3. Quality of life in low-income men after surgical castration for metastatic prostate cancer;Urologic Oncology: Seminars and Original Investigations;2022-07

4. Androgen deprivation therapy for prostate cancer: Prescribing behaviors and preferences among urologists;Canadian Urological Association Journal;2022-05-20

5. Time trends of drug-specific actionable adverse events among patients on androgen receptor antagonists: Implications for remote monitoring;Canadian Urological Association Journal;2021-08-16

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3